Literature DB >> 27067984

Venous thromboembolism and occult cancer: impact on clinical practice.

Afshan Gheshmy1, Marc Carrier2.   

Abstract

Unprovoked venous thromboembolism (VTE) can be the first manifestation of cancer. Given this relationship between unprovoked VTE and cancer, it is appealing for clinicians to screen their patients with a first episode of acute unprovoked VTE for a potential occult malignancy. Five different studies have compared a limited (thorough history and physical exam, basic bloodwork) to a more extensive occult cancer screening strategy (e.g. computed tomography, fludeoxyglucose positron emission tomography, etc.). Most of these studies have failed to show that an extensive occult cancer screening strategy diagnoses more occult cancer (including early cancers), misses fewer cancers during follow-up or improves overall and/or cancer-related mortality suggesting that extensive occult cancer screening should not be performed routinely. Therefore, patients with a first unprovoked VTE should undergo a limited cancer screening only and clinicians should ensure that their patients are up to date regarding age- and gender- specific cancer screening (colon, breast, cervix and prostate) as per their national recommendations. Current evidence does not support a net clinical benefit to perform an extensive occult cancer screening on all patients, and a decision to do additional testing should be made on a case by case basis.
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Malignancy; Venous thromboembolism; Venous thrombosis

Mesh:

Year:  2016        PMID: 27067984     DOI: 10.1016/S0049-3848(16)30091-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Dimethyl 2,2'-[2,2'-(ethane-1,1-diyl)bis(1H-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect.

Authors:  Yaonan Wang; Haiyan Chen; Xiaoyi Zhang; Lin Gui; Jianhui Wu; Qiqi Feng; Shiqi Peng; Ming Zhao
Journal:  Int J Nanomedicine       Date:  2018-11-22

2.  Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?

Authors:  Filipa Ferreira; José Pereira; Ana Lynce; José Nunes Marques; Ana Martins
Journal:  Cureus       Date:  2020-02-10

3.  Venous thromboembolism and cancer risk.

Authors:  Per Sandén; Peter J Svensson; Anders Själander
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

4.  Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism.

Authors:  Luis Jara-Palomares; Remedios Otero; David Jimenez; Juan Manuel Praena-Fernandez; Carme Font; Conxita Falga; Silvia Soler; David Riesco; Peter Verhamme; Manuel Monreal
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.